Psychopharmacology of Eating Disorders

B. Timothy Walsh, M.D.

New York State Psychiatric Institute
Columbia University Medical Center
www.eatingdisordersclinic.org

Pre-Lecture Questions Follow

1. The following agent has been demonstrated to be effective in the treatment of anorexia nervosa.

- a. Olanzapine
- b. Fluoxetine
- c. Imipramine
- d. None of the above

2. The following class(es) has/have convincing data from placebo-controlled trials supporting its/their utility in the treatment of bulimia nervosa.

- a. Anticonvulsants
- **b.** Antipsychotics
- c. Antidepressants
- d. All of the above
- e. None of the above

3. The dose of fluoxetine established to be most effective in the treatment of bulimia nervosa is:

- a. 10 mg/d
- **b.** 20 mg/d
- **c.** 40 mg/d
- d. 60 mg/d
- e. 80 mg/d

4. In controlled trials, at least one-half of the anti-bulimic effect of fluoxetine is apparent within (choose the shortest correct answer):

- a. 5 days
- b. 2 weeks
- c. 6 weeks
- d. 3 months
- e. 6 months

5. The following class(es) has/have data from placebocontrolled trials supporting its/their utility in the treatment of binge eating disorder:

- a. Anticonvulsants (e.g. topiramate)
- **b.** Weight loss agents (e.g. sibutramine)
- c. Antidepressants
- d. All of the above
- e. None of the above

Psychopharmacology of Eating Disorders

Three syndromes to be considered:

- Anorexia Nervosa
- Bulimia Nervosa
- Binge Eating Disorder

Anorexia Nervosa

Among the interventions proposed in the literature as being effective are the following somatic treatments:

- Thyroid Hormone
- ACTH
- Lobotomy
- ECT
- Chlorpromazine
- + Insulin
- Amitriptyline

- Lithium
- Phenoxybenzamine
- Domperidone
- THC
- Cyproheptadine
- Fluoxetine
- Olanzapine

Is any of this the 'Right Stuff'?

The only way to know is via placebo-controlled trials.

Psychopharmacology of Anorexia Nervosa Clinical Characteristics

Patients in studies are:

underweight (required by diagnostic criteria) usually hospitalized

(in real world, most patients are outpatients)

usually adults

(though the illness usually starts in adolescence, most patients presenting for treatment are over 18)

Psychopharmacology of Anorexia Nervosa Rationale for Agents Examined

- Take advantage of side effects
 Weight gain
- Or, treat symptoms which are often prominent in Anorexia Nervosa

Psychotic-like thinking about weight

Depression

OCD

Anorexia Nervosa: Controlled Trials Conducted

- Antipsychotics
- Antidepressants
- Serotonin Antagonists
- Lithium
- THC
- Cisapride
- Zinc

Anorexia Nervosa: Controlled Trials

<u>Class</u> <u>Results*</u>	# Trials	<u>Medication</u>		
Antipsychotic	2	Sulpiride, Pimozide	-	
Antidepressant	4	CMI, AMI (2), FLX	-	
Serotonin Antagonis	t 3	Cyproheptadine	+/-	
Lithium	1		-	
THC	1		-	
Cisapride	1		+/-	
Zinc '-' indicates no better than placebo '+/-' indicates small, clinically unimpressive effects				


Anorexia Nervosa Controlled Trial of Fluoxetine

The next two slides illustrate the general pattern of medication trials of anorexia nervosa.


The first slide shows increase in weight; the second shows decrease in depression (assessed by the Beck Depression Inventory).

This is the *only* controlled trial of an SSRI in underweight patients with anorexia nervosa.

Fluoxetine vs. Placebo in Anorexia Nervosa



Fluoxetine vs. Placebo in Anorexia Nervosa



Anorexia Nervosa: Summary of Controlled Trials in Underweight Patients

- Only a very small number of trials.
- But, no evidence of utility of any agent.
- Perhaps medications are ineffective because malnutrition causes neurochemical changes that interfere with actions of medications.
- Therefore, several studies have begun to examine the utility of medications in preventing relapse among patients who have recently regained weight.

Anorexia Nervosa: SSRI's for Relapse Prevention

- Strober et al (1997)
 66 weight-restored adolescents
 33 on fluoxetine, 33 case controls
 No difference
- Kaye et al (2001)
 35 wight-restored patients
 Fluoxetine vs Placebo
 Lower relapse rate on fluoxetine
- Walsh, Kaplan, et al (2006)
 93 weight-restored patients
 Fluoxetine vs Placebo
 Results pending....

Psychopharmacology of Anorexia Nervosa New Ideas

Olanzapine

4 open trials reported.

Some patients gain weight, but many are unwilling to take it or to remain on it.

Placebo-controlled data needed.

Psychopharmacology of Anorexia Nervosa Summary

- No medication clearly effective in underweight patients.
- Unknown whether antidepressants may reduce rate of relapse.
- Rumors of utility of olanzapine more data needed.
- Best biological treatment is calories!

Bulimia Nervosa

Controlled trials have been conducted of the following agents:

- Anticonvulsants
- Lithium
- Fenfluramine
- Antidepressants
- 5-HT3 antagonist (ondansetron)
- Topiramate

By far, antidepressants are the most studied, and have most convincing evidence of efficacy. Therefore, will focus on that class.

Psychopharmacology of Bulimia Nervosa Clinical Characteristics

Patients in studies usually:
 use vomiting to compensate
 (DSM-IV allows other methods)
 are of normal weight
 are almost all female
 are young adults


Bulimia Nervosa Rationale for Antidepressants

- Comorbidity with depression
- Role of serotonin in satiety


Controlled Trials of Antidepressants in Bulimia Nervosa

<u>Author</u>	<u>Medication</u>	<u>n</u>	
<u>Length(wks)</u>			
Sabine et al	Mianserin	36	8
Pope et al	Imipramine	19	8
Mitchell & Groat	Amitriptyline	32	8
Hughes et al	Desipramine	22	6
Walsh et al	Phenelzine	50	6
Agras et al	Imipramine	22	16
Kennedy et al	Isocarboxazid	18	6
Barlow et al	Desipramine	24	6
Blouin et al	Desipramine	10	6
Horne et al	Bupropion	49	8
Pope et al	Trazodone	42	6
Mitchell et al	Imipramine	74	10
Enas et al	Fluoxetine	382	8
Walsh et al	Desipramine	78	6
Wheadon et al	Fluoxetine	390	16
Kennedy et al	Brofaromine	36	8
Alger et al	Imipramine	22	8
Freeman et al	Fluvoxamine		8

Antidepressant Treatment of Bulimia Nervosa



Bulimia Nervosa: Time Course of Response to Fluoxetine



Fluoxetine, at 60 mg/d, was initiated on Day 1. Note rapidity of response! Was well-tolerated.

Notes on Previous Slides

- Much variability in placebo response, and no head-to-head trials of different medications.
- In virtually all trials, antidepressant treatment is associated with greater improvement than placebo.
- Fluoxetine (60 mg/d) is superior to placebo; 20 mg/d is not.
- Fluoxetine is only SSRI with evidence of efficacy, and only medication FDAapproved for bulimia.

Bulimia Nervosa: Concerns re Antidepressant Treatment

- Psychotherapy works at least as well
- Single course of a single drug only rarely produces complete remission of symptoms.
- Side effects, etc.

So, psychotherapy (CBT) usually firstchoice treatment

 There is some evidence that adding medication to psychotherapy is beneficial, but only modestly.

Psychopharmacology of Bulimia Nervosa New Ideas

Ondansetron Topiramate

Ondansetron vs Placebo

Faris et al, 2000

- 5HT3 antagonist
- Effective anti-emetic
- A single small study indicates efficacy versus placebo in patients with refractory BN

Topiramate for Bulimia Nervosa

Topiramate

Effective anti-epileptic.

Appears effective in obesity.

A single placebo controlled trial in bulimia supports efficacy.

Side effects (e.g., cognitive slowing, paresthesias, kidney stones) potentially problematic.

Psychopharmacology of Bulimia Nervosa Summary

- Antidepressants reduce symptoms
- Fluoxetine is only SSRI studied well tolerated at 60 mg/day
- CBT also clearly effective combine treatments?
 sequence treatments?
- Experimental ondansetron, topiramate

Binge Eating Disorder: Key Diagnostic Features

- Recurrent binge eating (objectively large amount of food and loss of control) (same as bulimia)
- No compensatory behavior (clearly different from bulimia)
- Marked distress about the behavior

Binge Eating Disorder Clinical Features

Compared with patients with anorexia nervosa and bulimia nervosa, those with Binge Eating Disorders:

are older (~middle aged) more frequently male (40-50%)

Most are overweight or obese.

Low levels of mood and anxiety disturbance are common.

Goals of Treatment for Obese Patients With BED

- Normalization of eating patterns and cessation of binge eating (BEHAVIORAL)
- Management of obesity (SOMATIC)
- Reduction of overall distress: remediation of depressive symptoms and enhanced selfacceptance (PSYCHOLOGIC)

Medications Examined for Treatment of BED

Antidepressants

TCAs: desipramine, imipramine

SRIs: fluvoxamine, sertraline, fluoxetine,

citalopram

- FDA approved antiobesity agents sibutramine orlistat
- Other
 NaltrexoneTopiramate


Controlled Trials of Medication in BED

Length

Author	Medication(s)	N	(weeks)
McCann (1990)	Desipramine	23	12
Alger (1991)	Imipramine Naltrexone	55	8
Stunkard (1996)	d-Fenfluramine*	28	8
Hudson (1998)	Fluvoxamine	85	9
McElroy (2000)	Sertraline	34	6
Arnold (2002)	Fluoxetine	60	6
McElroy (2003)	Citalopram	38	6
McElroy (2003)	Topiramate	58	14
Appolinario (2003)	Sibutramine	60	12
Grilo (2005)	Orlistat	50	12


^{*}Removed from the market.

Efficacy of Medication for Treatment of BED



Efficacy of Medication for Treatment of BED

Weight Loss (kg)



Conclusions: Treatment of Binge Eating Disorder

A range of treatments appear effective in reducing binge eating frequency and improving symptoms of mood disturbance.

Several forms of psychological treatment are effective. Antidepressants are effective.

The most effective interventions to aid weight loss appear to be interventions effective for obesity, in general:

sibutramine orlistat topiramate

A significant problems in evaluating these data is the high rate of symptomatic improvement in response to non-specific interventions (i.e., a high placebo response).

Psychopharmacology of Eating Disorders Summary

- Anorexia Nervosa
 No medication of proven utility!
 Calories and psychotherapy.
- Bulimia Nervosa

First line: SSRI's (fluoxetine).

Second line: SNRI? Topiramate?

Binge Eating Disorder

Many interventions appear helpful, but best approach is uncertain at present.

Unsolicited Advertisements

Available at NYSPI/Columbia are:

free treatment for research participants: Anorexia Nervosa, Bulimia Nervosa, Binge Eating post-graduate fellowship opportunities

www.eatingdisordersclinic.org

Post-Lecture Questions Follow

1. The following agent has been demonstrated to be effective in the treatment of anorexia nervosa.

- a. Olanzapine
- b. Fluoxetine
- c. Imipramine
- d. None of the above

2. The following class(es) has/have convincing data from placebo-controlled trials supporting its/their utility in the treatment of bulimia nervosa.

- a. Anticonvulsants
- b. Antipsychotics
- c. Antidepressants
- d. All of the above
- e. None of the above

3. The dose of fluoxetine established to be most effective in the treatment of bulimia nervosa is:

- a. 10 mg/d
- **b.** 20 mg/d
- **c.** 40 mg/d
- d. 60 mg/d
- e. 80 mg/d

4. In controlled trials, at least one-half of the anti-bulimic effect of fluoxetine is apparent within (choose the shortest correct answer):

- a. 5 days
- b. 2 weeks
- c. 6 weeks
- d. 3 months
- e. 6 months

5. The following class(es) has/have data from placebocontrolled trials supporting its/their utility in the treatment of binge eating disorder:

- a. Anticonvulsants (e.g. topiramate)
- b. Weight loss agents (e.g. sibutramine)
- c. Antidepressants
- d. All of the above
- e. None of the above

Answers:

- 1) d
- C
- 2) 3) d
- 4) b
- 5) d